South African Guidelines for the Management of Community Acquired Pneumonia in Adults Guideline writing committee

(119) Siemieniuk RA, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med 2015 Oct 6;163(7):519-528.

(120) Wan YD, Sun TW, Liu ZQ, Zhang SG, Wang LX, Kan QC. Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Chest 2016 Jan;149(1):209-219.

(121) Feldman C, Anderson R. Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis 2016 Mar;8(3):E162-71.

(122) Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. 1996;275:134-141.

(123) Sligl WI, Eurich DT, Marrie TJ, Majumdar SR. Age still matters: prognosticating short- and long-term mortality for critically ill patients with pneumonia. Crit Care Med 2010 Nov;38(11):2126-2132.

(124) Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013 Feb;39(2):165-228.

(125) Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, et al. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med 2015 Feb 19;372(8):747-755.

(126) Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012 Sep 12;(9):CD004418. doi(9):CD004418.

(127) Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Lim WS, Al Mamun A, et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses 2016 May;10(3):192-204.

(128) Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Rev Port Pneumol 2009 Jan-Feb;15(1):129-132.

(129) Nathwani D, Lawson W, Dryden M, Stephens J, Corman S, Solem C, et al. Implementing criteria-based early switch/early discharge programmes: a European perspective. Clin Microbiol Infect 2015 Sep;21 Suppl 2:S47-55.

(130) Oosterheert JJ, Bonten MJ, Schneider MM, Buskens E, Lammers JW, Hustinx WM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006 Dec 9;333(7580):1193.

(131) Engel MF, Bruns AH, Hulscher ME, Gaillard CA, Sankatsing SU, Teding van Berkhout F, et al. A tailored implementation strategy to reduce the duration of intravenous antibiotic treatment in community-acquired pneumonia: a controlled before-and-after study. Eur J Clin Microbiol Infect Dis 2014 Nov;33(11):1897-1908.

(132) Seedat MA, Feldman C, Skoularigis J, Promnitz DA, Smith C, Zwi S. A study of acute community-acquired pneumonia, including details of cardiac changes. Q J Med 1993 Oct;86(10):669-675.

(133) Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007 Jul 15;45(2):158-165.

(134) Ramirez J, Aliberti S, Mirsaeidi M, Peyrani P, Filardo G, Amir A, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis 2008 Jul 15;47(2):182-187.

(135) Corrales-Medina VF, Suh KN, Rose G, Chirinos JA, Doucette S, Cameron DW, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011 Jun;8(6):e1001048.

(136) Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, Fine MJ. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012 Feb 14;125(6):773-781.

(137) Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the cardiovascular system. Lancet 2013 Feb 9;381(9865):496-505.

(138) Soto-Gomez N, Anzueto A, Waterer GW, Restrepo MI, Mortensen EM. Pneumonia: an arrhythmogenic disease? Am J Med 2013 Jan;126(1):43-48.

(139) Cangemi R, Casciaro M, Rossi E, Calvieri C, Bucci T, Calabrese CM, et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 2014 Nov 4;64(18):1917-1925.

(140) Feldman C, Anderson R. Community-Acquired Pneumonia: Pathogenesis of Acute Cardiac Events and Potential Adjunctive Therapies. Chest 2015 Aug;148(2):523-532.

(141) Falcone M, Russo A, Cangemi R, Farcomeni A, Calvieri C, Barilla F, et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc 2015 Jan 6;4(1):e001595.

(142) Brown AO, Mann B, Gao G, Hankins JS, Humann J, Giardina J, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog 2014 Sep 18;10(9):e1004383.

(143) Brown AO, Millett ER, Quint JK, Orihuela CJ. Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med 2015 Apr 1;191(7):739-745.

(144) Viasus D, Garcia-Vidal C, Manresa F, Dorca J, Gudiol F, Carratala J. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013 Jan;66(1):27-33.

(145) Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA 2015 Jan 20;313(3):264-274.

(146) Cangemi R, Calvieri C, Falcone M, Bucci T, Bertazzoni G, Scarpellini MG, et al. Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. Am J Cardiol 2015 Aug 15;116(4):647-651.

(147) Feldman C, Viljoen E, Morar R, Richards G, Sawyer L, Goolam Mahomed A. Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. 2001;6:323-330.

(148) Fine MJ, Orloff JJ, Arisumi D, Fang GD, Arena VC, Hanusa BH, et al. Prognosis of patients hospitalized with community-acquired pneumonia. 1990;88:1N-8N.

(149) Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. 2006;28:346-351.

(150) Loke YK, Kwok CS, Wong JM, Sankaran P, Myint PK. Chronic obstructive pulmonary disease and mortality from pneumonia: meta-analysis. 2013;67:477-487.

(151) Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. 1997;336:243-250.

(152) Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. 2014;3:Cd010115.

(153) Marik PE. Aspiration pneumonitis and aspiration pneumonia. 2001;344:665-671.

(154) Lode H. Microbiological and clinical aspects of aspiration pneumonia. 1988;21 Suppl C:83-90.

(155) Bartlett JG, Gorbach SL. The triple threat of aspiration pneumonia. 1975;68:560-566.

(156) Finegold SM. Aspiration pneumonia. 1991;13 Suppl 9:S737-42.

(157) Marik PE. Aspiration pneumonitis and aspiration pneumonia. 2001;344:665-671.

(158) Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. 1995;332:1280-1284.

(159) Aspiration pneumonia. 2009;14 Suppl 2:S59-64.

(160) Mullan H, Roubenoff RA, Roubenoff R. Risk of pulmonary aspiration among patients receiving enteral nutrition support. 1992;16:160-164.

(161) DiBardino DM, Wunderink RG. Aspiration pneumonia: a review of modern trends. 2015;30:40-48.

(162) Lipper B, Simon D, Cerrone F. Pulmonary aspiration during emergency endoscopy in patients with upper gastrointestinal hemorrhage. 1991;19:330-333.

(163) Rudolph SJ, Landsverk BK, Freeman ML. Endotracheal intubation for airway protection during endoscopy for severe upper GI hemorrhage. 2003;57:58-61.

(164) Reza Shariatzadeh M, Huang JQ, Marrie TJ. Differences in the features of aspiration pneumonia according to site of acquisition: community or continuing care facility. 2006;54:296-302.

(165) Fernandez-Sabe N, Carratala J, Roson B, Dorca J, Verdaguer R, Manresa F, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. 2003;82:159-169.

(166) Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. 1989;11:586-599.

(167) Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. 1991;144:312-318.

(168) Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. 1994;105:1487-1495.

(169) Taylor JK, Fleming GB, Singanayagam A, Hill AT, Chalmers JD. Risk factors for aspiration in community-acquired pneumonia: analysis of a hospitalized UK cohort. 2013;126:995-1001.

(170) Holas MA, DePippo KL, Reding MJ. Aspiration and relative risk of medical complications following stroke. 1994;51:1051-1053.

(171) Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. 2011;11:110.

(172) Leroy O, Vandenbussche C, Coffinier C, Bosquet C, Georges H, Guery B, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. 1997;156:1922-1929.

(173) Leroy O, Santre C, Beuscart C, Georges H, Guery B, Jacquier JM, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. 1995;21:24-31.

(174) Kozlow JH, Berenholtz SM, Garrett E, Dorman T, Pronovost PJ. Epidemiology and impact of aspiration pneumonia in patients undergoing surgery in Maryland, 1999-2000. 2003;31:1930-1937.

(175) Adnet F, Baud F. Relation between Glasgow Coma Scale and aspiration pneumonia. 1996;348:123-124.

(176) Mokhlesi B, Logemann JA, Rademaker AW, Stangl CA, Corbridge TC. Oropharyngeal deglutition in stable COPD. 2002;121:361-369.

(177) Nose M, Recla E, Trifiro G, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. 2015.

(178) Terpenning MS, Taylor GW, Lopatin DE, Kerr CK, Dominguez BL, Loesche WJ. Aspiration pneumonia: dental and oral risk factors in an older veteran population. 2001;49:557-563.

(179) Scannapieco FA, Papandonatos GD, Dunford RG. Associations between oral conditions and respiratory disease in a national sample survey population. 1998;3:251-256.

(180) Park RH, Allison MC, Lang J, Spence E, Morris AJ, Danesh BJ, et al. Randomised comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding in patients with persisting neurological dysphagia. 1992;304:1406-1409.

(181) Bartlett JG. How important are anaerobic bacteria in aspiration pneumonia: when should they be treated and what is optimal therapy. 2013;27:149-155.

(182) Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. 1993;16 Suppl 4:S248-55.

(183) Finegold SM, George WL, Mulligan ME. Anaerobic infections. Part I. 1985;31:1-77.

(184) Moser KM, Maurer J, Jassy L, Kremsdorf R, Konopka R, Shure D, et al. Sensitivity, specificity, and risk of diagnostic procedures in a canine model of Streptococcus pneumoniae pneumonia. 1982;125:436-442.

(185) Mier L, Dreyfuss D, Darchy B, Lanore JJ, Djedaini K, Weber P, et al. Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures. 1993;19:279-284.

(186) Marik PE, Careau P. The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study. 1999;115:178-183.

(187) El-Solh AA, Pietrantoni C, Bhat A, Aquilina AT, Okada M, Grover V, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. 2003;167:1650-1654.

(188) El-Solh AA, Vora H, Knight PR,3rd, Porhomayon J. Diagnostic use of serum procalcitonin levels in pulmonary aspiration syndromes. 2011;39:1251-1256.

(189) Finegold SM. Aspiration pneumonia. 1991;13 Suppl 9:S737-42.

(190) Bartlett JG, Finegold SM. Anaerobic infections of the lung and pleural space. 1974;110:56-77.

(191) Bartlett JG, Gorbach SL. The triple threat of aspiration pneumonia. 1975;68:560-566.

(192) Mendelson CL. The aspiration of stomach contents into the lungs during obstetric anesthesia. 1946;52:191-205.

(193) Levison ME, Mangura CT, Lorber B, Abrutyn E, Pesanti EL, Levy RS, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. 1983;98:466-471.

(194) Gudiol F, Manresa F, Pallares R, Dorca J, Rufi G, Boada J, et al. Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. 1990;150:2525-2529.

(195) Perlino CA. Metronidazole vs clindamycin treatment of anerobic pulmonary infection. Failure of metronidazole therapy. 1981;141:1424-1427.

(196) Kadowaki M, Demura Y, Mizuno S, Uesaka D, Ameshima S, Miyamori I, et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. 2005;127:1276-1282.

(197) Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H, German Lung Abscess Study, Group. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. 2008;36:23-30.

(198) Tokuyasu H, Harada T, Watanabe E, Okazaki R, Touge H, Kawasaki Y, et al. Effectiveness of meropenem for the treatment of aspiration pneumonia in elderly patients. 2009;48:129-135.

(199) Green RJ, Feldman C, Schoub B, Richards GA, Madhi SA, Zar HJ, et al. Influenza guideline for South Africa--update 2008. S Afr Med J 2008 Mar;98(3 Pt 2):224-230.

(200) Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010 Sep 3;59(34):1102-1106.

(201) Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012 Jun 1;61(21):394-395.

(202) Pfizer laboratories (Pty) Ltd. Prevenar 13 suspension for injection. Final approved Package Insert – 26 November 2015. .

(203) Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012 Oct 12;61(40):816-819.

(204) Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014 Sep 19;63(37):822-825.

(205) French N, Gordon SB, Mwalukomo T, White SA, Mwafulirwa G, Longwe H, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010 Mar 4;362(9):812-822.

(206) Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015 Mar 19;372(12):1114-1125.